Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740050 | 1.00 | SMYD2 (0.41) | SMYD2CYP1A2TOP2ACYP3A4HTT | |
| SCHEMBL1739798 | 1.00 | SMYD2 (0.41) | SMYD2CYP1A2TOP2ACYP3A4HTT | |
| SCHEMBL1117861 | 0.92 | SMYD2 (0.40) | SMYD2TOP2ACYP3A4HTTSMN1; SMN2 | |
| SCHEMBL52552 | 0.82 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL29946810 | 0.82 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL18026905 | 0.82 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL9274167 | 0.81 | TOP2A (0.40) | SMYD2TOP2A | |
| SCHEMBL9266676 | 0.81 | TOP2A (0.40) | SMYD2TOP2A | |
| SCHEMBL28346561 | 0.79 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL6412838 | 0.79 | SMYD2 (0.41) | SMYD2TOP2ACYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466072-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2994469-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Gilead Sciences, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014182929-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | WO | disclosed |
| EP-0544010-B1 | PROCESS FOR PRODUCING 2',3'-DIDEOXY-BETA-NUCLEOSIDE | JAPAN TOBACCO INC (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5416204-A | Method for preparing 2'-3'-dideoxy-β-nucleosides using 2,2-dideoxy-di(organothio)-pentofuranose intermediates | JAPAN TOBACCO, INCORPORATED (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0544010-A1 | PROCESS FOR PRODUCING 2',3'-DIDEOXY-BETA-NUCLEOSIDE | JAPAN TOBACCO INC. (JP) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMYD2 1518/4885CYP1A2 3097/4885TOP2A 1315/4885 |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | SMYD2 3468/4885CYP1A2 1425/4885TOP2A 2421/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | SMYD2 1518/4885CYP1A2 3097/4885TOP2A 1315/4885 |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMYD2 1450/4885CYP1A2 3113/4885TOP2A 1318/4885 |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMYD2 1518/4885CYP1A2 3097/4885TOP2A 1315/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMYD2 1486/4885CYP1A2 3133/4885TOP2A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.